TRANSVAC2 offers technical services at all stages of the Vaccine R&D pipeline to support the development of prophylactic and therapeutic vaccines for human and veterinary use.
Now you can access TRANSVAC services via ISIDORe
TRANSVAC: New Vaccines Faster
TRANSVAC is a collaborative infrastructure project funded by the European Commission (EC), initially under the 7th Framework Programme (FP7) and currently under Horizon 2020. The project is a joint effort of leading European groups working in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development.
TRANSVAC2 is now also offering services as part of ISIDORe, Integrated Services for Infectious Disease Outbreak Research, to support scientists and their research on epidemic- and pandemic-prone pathogens. The ISIDORe project assembles the largest and most diverse research and service-providing instrument to study infectious diseases in Europe, with expertise from structural biology to clinical trials.
ISIDORe brings together under the same umbrella 17 major European life sciences research infrastructures and infectious diseases networks, including to accelerate the generation of new knowledge and intervention tools to enhance Europe’s capacity for controlling (re)emerging and epidemic infectious diseases, starting with the COVID-19 pandemic. Check out the services available and apply now!
Support to development of vaccines against COVID19
“Rapid progress towards the development of potent vaccines can only happen through concerted and coordinated efforts around Europe and the world – and TRANSVAC2 is well positioned to facilitate such efforts.” - Dr. Hilde Depraetere, TRANSVAC2 Coordinator
To support of the global effort to accelerate the development of a vaccine against Sars-CoV-2, TRANSVAC2 launched in April 2020 a specific call for applications focused on the development of novel COVID-19 vaccines.
Consequently, a variety of TRANSVAC2 services, from antigen discovery to preclinical and clinical trial support (In total 31 services), will be delivered to help eight awarded research groups from SMEs and public institutions to speed-up the COVID-19 vaccine development pipeline.
This initiative is fully supported by the European Commission which provides, additional top-up funds worth EUR 4 millions.
Excerpt adapted from https://ec.europa.eu/research/infocentre/article_en.cfm?artid=49836